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LETTERS TO THE EDITOR 
Detection of Amiodarone Pulmonary Toxicity 
In a recent editorial. Horowitz (I) concluded that serial pulmonary 
function testing, including diffusing capacity of carbon monoxide. is 
not cost-effective for patients treated with amiodarone. We concur. 
although we have arrived at our conclusion by a somewhat different 
path of reasoning. Horowitz was reacting to a study by Magro et al. 
(2) that demonstrated that a decrease in the diffusing capacity of 
carbon monoxide is of little value in predicting which patients may 
develop interstitial pulmonary complications. Nevertheless. the 
study included a recommendation for routine pulmonary function 
screening because of the high incidence (17%) of pulmonary toxicity 
and the high diagnostic accuracy of a positive diffusing capacity of 
carbon monoxide in symptomatic patients. According to Horowitz. 
the incidence and seriousness of pulmonary toxicity make screening 
desirable but. in the absence of symptoms. such screens produce an 
unacceptably high number of false positive results. He also points 
out that serial pulmonary tests cost as much as the therapy itself. 
Kowey et al. (3) have made the same assertions, and I believe the 
majority of arrhythmologists would agree with them. 
However, Horowitz (I) neglected one very significant finding by 
Magro et al. (2): development of amiodarone pulmonary toxicity 
was significantly related to high maintenance doses. In view of this 
relation, in 1984 Magro et al. recommended a reduction in the 
maintenance dose to 200 to 400 mgiday (2). In December 1985. these 
investigators also lowered the loading dose from approximately 
1,400 to I.000 mgiday. This completely eliminated pulmonary tox- 
icity during loading. With this low dose regimen. from January I984 
to 1987, Magro et al. confirmed a drastic decrease in the overall 
incidence of pulmonary toxicity from I7 to S% (4). During the last 2 
years of follow-up, Magro et al. did not see a single case of 
amiodarone toxicity. an outcome that they attribute to these dose 
reductions (4). 
Our own experience with amiodarone agrees with what Magro et 
al. (2) finally achieved with lowered loading and maintenance doses. 
In a prospective study of 1 IO patients, using loading doses of 600 to 
800 mg and maintenance doses of 200 to 400 mg, my colleagues and 
I(5) did not find a single case of pulmonary toxicity. In fact, perhaps 
because I used the European experience to guide dosage, 1 have yet 
to see pulmonary toxicity develop in one of my patients receiving 
amiodarone. 
T!irt.s. tirr wry low ithlcncf~ of pultnot7uty toxicity n,it/z the /OW 
dosrs of crtniodurottc~ c~rrrrcnrly bring pru.rcribed tnukes phot~cq 
.smenitt,q .sttpcreropttory. A positive diffusing capacity of carbon 
monoxide test result. followed up by a gallium scan. has great merit 
in the rare. symptomatic patient with pulmonary infiltrates, but 
together they are impractical, costly and unpredictable screening 
devices. 
A dose relation has been evident from the earliest reports 01 
pulmonary toxicity with amiodarone. Rotmensch et al. (6), the first 
to report a case of amiodarone pneumonitis, put their findings in 
perspective I year later: among 400 patients treated with amioda- 
Tone, only 2 (0.5%) developed pulmonary toxicity (7). Both patients 
were receiving doses of 600 to 800 mgiday instead of the usual 200 to 
400 mgiday 
Noting the wide disparity between incidence of amiodarone 
pulmonary toxicity in Europe and that reported in early U.S. trials. 
Rotmensch et al. (7) attributed it to the high doses reported by 
American investigators. Daily maintenance doses of 800 to 1,200 mg 
over a 6 month period were not unusual (8-10). Rotmensch et al. (7) 
suggested “_ that the results of programmed cardiac stimulation 
in guiding the dosage of amiodarone may have misled the physician 
to further escalate its dosage [since it was not then known] that 
continued inducibility of arrhythmia may not indicate failure of the 
drug or its dosage.” 
The fact that Krikler (I I) observed only one case of toxicity in 
>I.000 arrhythmic patients during I3 years of using low doses of 
amiodarone seems to bear out such assertions. Other investigators 
(8,I2.13) who encountered pulmonary toxicity with amiodarone 
quickly recognized and responded to the relation. Marchlinski et al. 
(IO) found no pulmonary toxicity among 47 patients treated with 
maintenance doses of 400 mgiday, but they found a 17% incidence in 
the 23 patients receiving 600 to 800 mgiday. By lowering the dose. 
these investigators cut back the incidence to ~2”; at their center 
(14). 
A large retrospective study by Zipes and coworkers (IS) sup- 
ports this dose relation. Among 498 patients receiving amiodarone. 
only 4% developed pneumonitis. and the mean maintenance dose 
was 20% higher in those patients than in the 96% who did not 
develop pulmonary toxicity (15). 
In addition to Magro et al. (2.4). two other centers have studied 
the dose relation prospectively (3,16). Adams et al. (16) found that 
patients on daily doses of 1400 mg did not develop signs or 
symptoms of pulmonary toxicity, whereas 27% of those receiving 
higher doses (usually 600 mgiday) did: “One striking finding was 
that as maintenance doses were lowered from >600 mgiday to ~400 
mg/day the decline in Dco [diffusing capacity of carbon monoxide] 
slowed or stopped.” Four years after the study ended, 30 of the 33 
patients studied were still taking amiodarone and were well con- 
trolled with doses of 5400 mg. 
To determine whether lower doses would continue to yield a 
satisfactory clinical response. Kowey et al. (3) prospectively studied 
the efficacy and safety of low maintenance doses of amiodarone 
(mean 317 + I I4 mg) in 68 patients, most of whom had malignant 
ventricular arrhythmias: “Results indicated that amiodarone was a 
safe and effective antiarrhythmic drug when used in lower doses.” 
Life-threatening ventricular tachycardia was suppressed in 77% of 
patients refractory to other therapy and the incidence of pulmonary 
toxicitv was 4%. 
The fact that pulmonary toxicity occurs most frequently at the 
beginning of treatment suggests that there may be a relation between 
the degree of loading and this complication. The average cumulative 
amount of amiodarone used for loading in five reported studies 
(9.14.17-19) employing a high dose approach was 31.9 g. In contrast, 
the average loading dosage of five low dose amiodarone series 
(3,5.20-22) was 7.2 g. The combined average incidence of pulmo- 
nary complications was very low (0.55%) in these series. 
Itt cottc~lrrsiot~, we concur that screening for pulmonary toxicity 
during amiodarone therapy is a waste of time and money mainly 
because current dosing practices have made it unnecessary. There is 
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an overwhelming consensus that low doses have largely eliminated 
pulmonary toxicity as a reason to withdraw amiodarone therapy in 
the first place. As Magro et al. (2) put it, “ to withhold or 
withdraw potentially lifesaving therapy from patients frequently 
resistant to all other available antiarrhythmic medications based on 
preexisting abnormalities or a reduction in pulmonary function alone 
does not appear to be justified in the case of amiodarone.” 
In the use of amiodarone one has to remember that “poison is in 
everything, and no thing is without a poison. The dosage makes it 
either a poison or a remedy” (23). 
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Reply 
I agree with Kerin and Rubenfire that the incidence of pulmonary 
toxicity caused by amiodarone is reduced when the loading and 
maintenance doses of amiodarone are lowered. I appreciate their 
agreement that routine serial pulmonary function studies are not 
indicated in the follow-up of patients receiving amiodarone therapy. 
LEONARD N. HOROWITZ. MD. FACC 
Presbyterian Medical Center 
39th and Marker Streets 
Philadelphia, Pennsylvania 19104 
Dilated Cardiomyopathy 
Dystrophy 
in Myotonic 
Nguyen et al. (1) noted that 6 of their 12 autopsy cases of myotonic 
dystrophy had cardiac enlargement that was consistent with dilated 
cardiomyopathy in 3 cases. They cite other authors who have 
observed clinically undiagnosed cardiomegaly in autopsy cases. 
Perloff et al. (2) did not find echocardiographic evidence of ventric- 
ular dysfunction in their patients. We report a patient with the 
uncommon association of myotonic dystrophy and dilated cardio- 
myopathy with clinically overt congestive heart failure in the 
absence of an underlying chronic rhythm disturbance. 
A 42 year old white man with a history of progressive “hand 
stiffness” since adolescence presented to his family doctor with a 2 
year history of increasing shortness of breath and was found to be in 
congestive heart failure. He was transferred to our center for cardiac 
evaluation. On physical examination there was a paucity of cardio- 
vascular findings. The heart tones were distant; there was no atria1 
or ventricular gallop, murmur or increased jugular venous pressure. 
Chest radiographs showed massive cardiomegaly and mild pulmo- 
nary vascular congestion. The electrocardiogram showed normal 
sinus rhythm with left bundle branch block and a slightly prolonged 
PR interval (0.21 s). 
M-mode and two-dimensional echocardiography demonstrated a 
dilated, poorly contracting left ventricle with markedly diminished 
left ventricular ejection fraction (~10%). At cardiac catheterization, 
the right heart pressures were normal (right ventricle 20112 and 
pulmonary artery 2011.5 mm Hg, mean 18). The pulmonary capillary 
wedge pressure was 14 mm Hg and left ventricular pressure 90115 
mm Hg. There was mild systemic hypotension (aorta 90170 mm Hg). 
Thermodilution cardiac output was markedly diminished (1.32 liters/ 
min). Pulmonary vascular resistance was not elevated, but systemic 
vascular resistance was elevated (4.12 dynes/slcmm5). Left ventric- 
